ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Caladrius Biosciences Inc

Caladrius Biosciences Inc (CLBS)

0.4264
0.00
(0.00%)
Cerrado 28 Diciembre 3:00PM
0.00
0.00
(0.00%)
Fuera de horario: -

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
0.4264
Postura de Compra
0.4264
Postura de Venta
0.43
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
0.4264
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
8,150,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.18
Beneficio por acción (BPA)
-2.56
turnover
-
Beneficio neto
-20.84M

Acerca de Caladrius Biosciences Inc

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the... Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201. Mostrar más

Sector
Health & Allied Services,nec
Industria
Insurance Carriers, Nec
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
2006

CLBS Últimas noticias

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens...

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified...

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual...

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing...

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial...

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins...

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company...

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

CLBS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Caladrius Biosciences?
El precio actual de las acciones de Caladrius Biosciences es US$ 0.4264
¿Cuántas acciones de Caladrius Biosciences están en circulación?
Caladrius Biosciences tiene 8,150,000 acciones en circulación
¿Cuál es la capitalización de mercado de Caladrius Biosciences?
La capitalización de mercado de Caladrius Biosciences es USD 3.48M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Caladrius Biosciences?
Caladrius Biosciences ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Caladrius Biosciences?
El ratio precio/beneficio de Caladrius Biosciences es -1.18
¿Cuál es la moneda de reporte de Caladrius Biosciences?
Caladrius Biosciences presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Caladrius Biosciences?
El último beneficio anual de Caladrius Biosciences es USD -20.84M
¿Cuál es la dirección registrada de Caladrius Biosciences?
La dirección registrada de Caladrius Biosciences es 651 N BROAD ST SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19709
¿Cuál es la dirección del sitio web de Caladrius Biosciences?
La dirección del sitio web de Caladrius Biosciences es www.caladrius.com
¿En qué sector industrial opera Caladrius Biosciences?
Caladrius Biosciences opera en el sector INSURANCE CARRIERS, NEC

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
INTZIntrusion Inc
US$ 2.167
(381.56%)
189.59M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
563.26M
HUBCWHub Cyber Security Ltd
US$ 0.035
(250.00%)
2.79M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.95M
LITMSnow Lake Resources Ltd
US$ 1.61
(82.95%)
131.98M
NEUPNeuphoria Therapeutics Inc
US$ 4.11
(-92.30%)
936.47k
VIRXViracta Therapeutics Inc
US$ 0.16
(-32.49%)
9.31M
PRFXPainReform Ltd
US$ 3.48
(-28.98%)
926.19k
AIREreAlpha Tech Corporation
US$ 2.56
(-28.49%)
8.26M
AVGRAvinger Inc
US$ 0.9721
(-24.05%)
2.11M
AILEiLearningEngines Inc
US$ 0.5932
(267.31%)
557.72M
GTIGraphjet Technology
US$ 0.967551
(185.83%)
398.75M
RGTIRigetti Computing Inc
US$ 17.08
(10.62%)
298.47M
XTIAXTI Aerospace Inc
US$ 0.03935
(-1.63%)
263.01M
QSIQuantum Si Inc
US$ 3.585
(66.74%)
250.36M
luvwetscent luvwetscent 3 minutos hace
Complete BS
ELTP
luvwetscent luvwetscent 4 minutos hace
.30 EOY
ELTP
glenn1919 glenn1919 4 minutos hace
edbl.................................https://stockcharts.com/h-sc/ui?s=edbl&p=D&yr=0&mn=2&dy=12&id=p84071410134
EDBL
stockinspector stockinspector 4 minutos hace
Try the search function on google and impress us!
WDLF
Monksdream Monksdream 4 minutos hace
Better opportunity elsewhere
BLUE
gdog gdog 4 minutos hace
I hear ya but the worm will turn NLST will have its day.
NLST
firebag1 firebag1 4 minutos hace
getting on board at these basement bargain levels is a no brainer.....adding
CGAC
badog badog 5 minutos hace
If our CEO wanted to (or could) help shareholders he would do so. At least most people would think so. The fact that he hasn't communicated...hasn't reported...hasn't responded to calls or emails....this has been a concern for years. What is the purpose of the silence? He can certainly run
ERHE
DrivenByPain DrivenByPain 5 minutos hace
Read This @ The Bottom https://www.otcmarkets.com/otcapi/company/financial-report/419561/content

The Split Wont/Can't Happen Till 2/14/2025 6 Months From Purchase Date Any Way.
SGDH
firebag1 firebag1 6 minutos hace
thanks Janet! 2025 will be ours
RDAR
ddls ddls 7 minutos hace
Here's the way it works folks.🤠

When a company that is listed on the stock market BS's investors as long as this company (20 years) and has nothing to show for it, the only way it's going to "run" is if they show EOY growth of at least 300% for starters.
BIEL
zab zab 8 minutos hace
https://www.cbsnews.com/news/biden-signs-50-bills-into-law-on-christmas-eve/

Even made the Bald Eagle the symbol of America, meanwhile trump was busy stuffing his 12th Bic Mac in his mouth, and then falling down, you know the stuff that trump likes to do.
Longstrongsilver Longstrongsilver 9 minutos hace
Not sure about US, but Canada is T+1 (even for OTC/USA securities) so cut off is Monday here

Edit to add: and even if US is still t+2 the cutoff would have been Friday (not Thursday )
AZRH
AprilFool AprilFool 9 minutos hace
Nearly 49k shares traded yesterday. Interesting. Highest volume in years.
TRDX
BullNBear52 BullNBear52 10 minutos hace
No.
zab zab 11 minutos hace
America has to watch the daily trump temper tantrum; he does represent those southern states perfectly. Those MAGA supporters love crying about themselves, they do not want to learn in school, the information might bother them, they do not want to seek any medical treatments for anything but want to
JustJack JustJack 14 minutos hace
Not much, if anything, to laugh about with this share selling scheme. 

Unless you are Steve or Alexoops I guess.  
AITX
YY1000 YY1000 16 minutos hace
There are two reasons cited for why the '953 patent cannot claim priority date from the '048 provisional: (1) the change from C2 to C1 (which ENTA argued was correcting a typographical error) and (2) "the disclosure of a broad genus in the ‘048 Provisional fails to provide written description suppor
ENTA PFE
sharkey1 sharkey1 16 minutos hace
BS rack 186, but I am glad to see you spending a lot of useless vile energy trashing people on this board,
takes a lot of time to come up the stuff you post.
ELTP
ddls ddls 16 minutos hace
Buy: 0 - Neutral: 129,911 - Sell: 13,816,260 😭

Friday 12/27/24
BIEL
yman yman 17 minutos hace
Hey Mungo did you try contacting the Ant man? If he thinks he has a real chance with his case, he may be interested in more shares. How many shares are you talking about, I might be interested.
NNLX

Su Consulta Reciente

Delayed Upgrade Clock